irst-generation drug-eluting stents (DES: paclitaxeleluting stent (PES) and sirolimus-eluting stent (SES)) are now available and widely used in percutaneous coronary interventions to reduce binary angiographic restenosis and the need for related target lesion revascularization in comparison with bare metal stents. [1] [2] [3] This benefit is related to inhibition of neointimal growth, as measured as angiographic late loss. In contrast, a major clinical concern, late stent thrombosis (LST) after DES implantation, is caused by incomplete endothelialization and persistence of uncovered stent struts and is more likely to occur in the patient population with less late loss. [4] [5] [6] A recent meta-analysis of 16 randomized trials showed some differences between PES and SES. 7 SES had more favorable effects on the inhibition of neointimal hyperplasia (NIH), regarded as less late loss, than did PES. In addition, SES was superior to PES in reducing the risk of LST. The discrepancy between PES and SES in the angiographic and clinical outcomes does not support the hypothesis that a larger late loss may have a protective role against LST. 4 Optical coherence tomography (OCT) using an occlusive or non-occlusive technique provides high-resolution images (approximately 10 μm) and detailed information on NIH, the presence of uncovered struts and thrombus within the stent, beyond that achieved with other intracoronary imaging modalities. [8] [9] [10] [11] [12] [13] [14] In the present study, the degree of neointimal growth and in-stent thrombus of the 2 types of DES were evaluated using angiography and OCT, and compared. There is a hypothesis that advanced neointimal stent coverage may protect against stent thrombosis. In the present study, differences in neointimal growth and prevalence of in-stent thrombus between paclitaxel-and sirolimus-eluting stent (PES and SES) were evaluated by optical coherence tomography (OCT). 
therapy with aspirin 100 or 200 mg/day and ticlopidine 200 mg/day before DES implantation. During this study period neither clopidogrel nor glycoprotein IIb/IIIa had been approved for clinical use in Japan. Exclusion criteria were (1) contraindication to aggressive antiplatelet therapy, (2) chronic renal failure (serum creatinine ≥2.5 mg/dl) without regular hemodialysis, (3) low ejection fraction of the left ventricle (<30%), (4) left main coronary disease or ostial lesions, and (5) lesions with large vessel diameter (>4 mm). The last 2 criteria were instituted because of expected difficulty in acquiring OCT images for the entire stented segments. The medical ethics committee of Nippon Medical School approved the study, and written informed consent was given by all patients before each catheterization procedure.
Clinical Demographics
Patient demographics were obtained from hospital chart review. Acute coronary syndrome was based on the guidelines of the American College of Cardiology/American Heart Association. 15 Stable angina pectoris was defined as a positive stress test and no change in the frequency, duration or intensity of chest symptoms within 4 weeks. Stent target lesions were identified by a combination of electrocardiographic and angiographic findings and wall motion abnormalities of the left ventricle. A serum creatinine value ≥2 mg/dl or regular hemodialysis qualified for definition of chronic renal failure.
Angiographic Analysis
Coronary angiograms were analyzed with a computerassisted, automated edge detection algorithm (CMS, MEDIS, Nuenen, The Netherlands) by an angiographer who was unaware of the clinical information and using a quantitative coronary angiogram (QCA). QCA was performed before and immediately after stenting, and at follow-up using the same angle of projection determined by the worst view before stenting. 16 In-stent restenosis was defined as ≥50% diameter stenosis at follow-up. Any abnormal angiographic findings, such as filling defect, haziness or aneurysm formation, were qualitatively evaluated using standard definitions.
OCT Imaging
Follow-up OCT examinations were performed after DES implantation according to a previously described procedure. 10 In brief, an occlusion catheter (Helios™, Avantec Vascular Corp, Sunnyvale, CA, USA) was positioned proximal to the stent, and an image catheter (ImageWire™, LightLab Imaging, Westford, MA, USA) distal to the stent. During image acquisition, the occlusion balloon was inflated at 0.4-0.8 atm and Ringer's lactate was infused at 0.6-1.0 ml/s. The image catheter was pulled from distal to proximal using a motorized pullback system at 1.0 mm/s, and continuous images were stored digitally for subsequent analysis.
Analysis and Definition of OCT Findings
Cross-sectional OCT images were analyzed at 1 mm inter- vals. Thickness of NIH inside all struts of the stent was measured. NIH of 0 μm thickness was the definition for an uncovered stent. The maximum distance between the inner strut surface and adjacent vessel surface greater than the thickness of the stent strut and polymer (164 μm for PES; 166 μm for SES) was defined as incomplete apposition. For each patient, the ratio of uncovered or malapposed struts was separately calculated as follows:
Ratio of uncovered (or malapposed) struts = no. of uncovered (or malapposed) struts/total no. of struts × 100 (%).
In the area analysis, stent area and lumen area were measured by multiple-point trace. Late loss on QCA was defined as the maximum difference between the stent diameter and lumen diameter on the same diagonal line in the cross-section of minimum lumen area. NIH area was calculated as stent area minus lumen area. NIH volume was calculated as an integral of NIH area within the stent. Percent NIH area was defined as: Percent NIH area = NIH area/stent area × 100 (%)
In-stent thrombus was defined as an irregular high-or lowbackscattering mass (red thrombus or white thrombus, respectively) protruding into the lumen. 17 In the cross-sections that included thrombus, the thickness of the thrombus was measured as the distance from the thrombus surface to the struts underlying the thrombus. Additionally, the distance from the cross-section of minimum lumen area to the cross-section of thrombus was measured (Figure 1) . The location of thrombus was equally divided as proximal, middle or distal to the stent segments, and as overlapping the segment. Inter-and intra-observer variabilities were assessed by evaluating 20 random cross-sectional images by 2 independent readers and by the same reader at 2 separate time points.
Clinical Follow-up and Antiplatelet Regimen
Regular monthly clinical visits occurred until the follow-up catheter procedure. Dual antiplatelet therapy was continued for the follow-up period if there were no major side-effects. Major adverse cardiac events were defined as acute coronary syndrome, LST, cardiac sudden death, and target lesion revascularization by coronary artery bypass surgery or percutaneous coronary intervention.
Statistical Analysis
Data are presented as mean ± SD. Categorical variables are presented as frequencies and were analyzed by either Fisher's exact test or chi-square test. Continuous data between different categories were compared by either MannWhitney U test or unpaired Student's t-test. Correlation between angiographic and OCT parameters (late loss) was analyzed by Pearson's correlation coefficient. In the case of significance, they were evaluated by linear regression analysis. A P value <0.05 was considered to be statistically significant.
Results

Baseline Characteristics
The study population consisted of 20 patients (20 segments) treated with PES (n=26) and 20 patients (20 segments) treated with SES (n=30). If multiple stents were used, they completely overlapped without gaps. Of the patients' baseline characteristics, the proportions of those with diabetes mellitus, acute coronary syndrome or chronic renal failure did not differ between the PES group and SES group. Ejection fraction and prescribed medications were also similar between the 2 groups ( Table 1) . Three overlapping stents were implanted in 1 patient in the PES group and in 4 patients in the SES group. All patients had received continuous dual antiplatelet therapy without major side-effects. No significant differences were noted between the 2 groups with regard to lesion and procedural characteristics, except for maximum inflation pressure ( Table 2 ). The maximum inflation pressure was higher in the SES group than in the PES group. 
Angiographic Findings and Major Adverse Cardiac Events
Angiographic data are summarized in Table 3 . Before the procedure, lesion length tended to be shorter in the PES group compared with the SES group. At follow-up, diameter stenosis in the PES group tended to be smaller than in the SES group. Late loss was significantly greater in the PES group than in the SES group. In-stent restenosis occurred in 10% of the PES patients and in 5% of the SES. One patient (5%) in the PES group underwent target lesion revascularization (SES implantation). No other major adverse cardiac events occurred. Consequently, the frequency of major adverse cardiac events did not differ between groups (5% PES group vs 0% SES group; P=0.31).
In the QCA analysis, filling defect, haziness or aneurysm was not found on the follow-up angiograms.
OCT Findings
There were no OCT procedure-related complications; 31 inadequate cross-sectional images (non-circumferential images) were excluded. A total of 3,958 struts in 441 crosssections of PES and 4,476 struts in 542 cross-sections of SES were analyzed. The prevalence of patients with any uncovered struts was similar between the PES and SES Values are n (%) or mean ± SD. AHA/ACC, American Heart Association/American College of Cardiology. Other abbreviations as in Table 1 . Values are n (%) or mean ± SD except for follow-up duration. NIH, neointimal hyperplasia. Other abbreviations as in Table 1. groups (90% vs 95%, respectively). In-stent thrombus was found in 10 patients (50%) of the PES group and in 3 patients (15%) of the SES group, and the frequency of patients with thrombus was significantly higher in the PES than in the SES group (Figure 2) . There was no difference in the uncovered struts ratio between patients with and without thrombus (9±9% vs 10±7%, respectively; P=0.70); 4 thrombi were red and 9 were white, and the mean thrombus thickness was 379±194 μm (range 160-930 μm). Of the 13 thrombi, 10 (77%) were identified in the cross-sections separated from those with minimal lumen area. The distance between the cross-section of the minimal lumen area and that of thrombus was 6.5±6.0 mm (range 0-21.7 mm). The location of thrombus was 2 proximal segments, 8 middle segments, including 2 overlapping segments, and 3 distal segments; 1 thrombus ranked above malapposed struts and the other 2 thrombi were located in bifurcations of side branches. Late loss in patients with thrombus (n=13) did not differ from those without thrombus (n=27) (0.40±0.42 vs 0.23±0.31 mm, respectively; P=0.15). The mean thickness of NIH was greater with PES than with SES (118±141 vs 31±39 μm; P<0.001). The distribution of NIH thickness at intervals of 50 μm is shown in Figure 3 . Although the maximum NIH thickness was greater with PES than with SES, the minimum NIH thickness did not differ. Ratios of uncovered struts and malapposed struts were lower for PES than for SES. NIH area, percent NIH area, and NIH volume were greater for PES compared with SES ( Table 3) .
In each group, there was a significant correlation between late loss on QCA analysis and late loss measured by OCT (Figure 4) . Late loss in patients with and without thrombus did not differ in either the PES or SES group (P=0.88 and 0.68, respectively) ( Figure 5) .
Intra-observer variability in the measurements of thickness (or distance) and area was 10±10 μm and 0.2±0.4 mm 2 , respectively. Interobserver variability of the same measurements was 11±13 μm and 0.3±0.4 mm 2 , respectively. Intraobserver agreement for presence of thrombus and thrombus classification was 100% and 92%, respectively, and the inter-observer agreement was 92% and 84%, respectively.
Discussion
The present study demonstrated that the incidence of thrombus was higher with PES in patients having greater late loss, NIH thickness, and NIH volume compared with SES. After implantation of a first-generation DES, advanced neointimal growth is not associated with a low risk of instent thrombus. Relationship between the distribution of neointimal thickness and stent type. In the paclitaxel-eluting stent (PES), the percentage of struts with neointimal thickness of 0, 10-50, 60-100, 110-150, 160-200, 210-250, and ≥260 μm is 5%, 41%, 18%, 11%, 7%, 4%, and 14%, respectively, and 15%, 71%, 8%, 4%, 1%, 0.3%, and 0.5%, respectively, in the sirolimuseluting stent (SES).
In our QCA analysis, late loss was greater in patients with PES than with SES, which is a similar result to that found by previous large-scale studies. 7, 18 Our OCT findings also showed that maximum NIH thickness was greater in the PES group than in the SES grp. Furthermore, late loss measured by OCT correlated with angiographic late loss. Therefore, patients with a larger late loss potentially have a segment covered by thicker NIH than do those with a smaller late loss. However, there are several limitations to precisely determining NIH inside the entire stent segment based on angiographic late loss. Firstly, late loss is usually measured at the point of minimum lumen diameter and might reflect the cross-section of minimum lumen area within the stent. It is understood that neointimal growth within the DES is not uniform. 6, 19 In our OCT analysis, PES had a greater NIH area and volume than SES, but the prevalence of patients with uncovered struts and minimum NIH thickness was similar between the PES and SES groups. These findings suggest that neointimal growth in PES may advance partially, but more heterogeneously, than in SES. Therefore, angiographic late loss does not reflect neointimal growth within the whole stent segment. In addition, some tissues inside the DES regarded as lumen loss may not be true NIH, rather other types of tissue, such as fibrin, fibrinoid or thrombus, according to previous pathohistological investigations. 5, 6, 20, 21 In fact, the thickness of in-stent thrombus measured by OCT was approximately 0.4 mm. Although thrombus is possibly recognized as angiographic lumen loss, qualitative angiographic detection of thrombus was nearly powerless in this study. Finally, late loss did not significantly differ between patients with and without thrombus. Our results therefore do not support the hypothesis that a larger late loss might reflect less risk of thrombus formation.
The incidence of thrombus identified by OCT was higher in the PES group than in the SES group. Regarding thrombogenicity, both of the drugs released from the stents, paclitaxel and sirolimus, enhance endothelial expression of tissue factors that have prothrombogenic effects. 22 A previous experimental study showed that relative to SES, reestablishment of a functional endothelium is delayed following PES implantation. 23 Another pathological validation study using atherectomy specimens showed that delayed (or incomplete) healing and the appearance of fibrinoid were more pronounced in PES than in SES. 20 As those reports imply, incomplete endothelialization of PES may contribute to the high incidence of thrombus formation relative to SES.
The uncovered struts ratio was similar between patients with and without thrombus, which conflicts with previous pathological findings indicating that the presence of uncovered stent struts is the most powerful predictor of LST after DES implantation. 5, 6 Nevertheless, incomplete endothelialization can be found even in restenotic lesions showing a large lumen loss after PES implantation. 20 Tissue structures inside the DES, such as fibrin and fibrinoid, may be regarded as NIH by OCT, so NIH determined by OCT may not be accompanied by complete endothelialization. A thrombus may form in the area covered by some tissue but lacking endothelialization. Another possibility is that crosssectional OCT images are limited for identification of uncovered struts under the thrombus. In any case, OCT may underestimate the uncovered struts of DES, and there may be a discrepancy in the assessment of endothelialization between in-vivo OCT images and postmortem pathological specimens.
Although all trials did not disclose clinical differences between PES and SES patients, a large-scale study showed that LST was more frequently observed with PES than with SES, 18 possibly because a higher frequency of latent thrombus with PES leads to a higher incidence of LST compared with SES. A 2-year angioscopic follow-up study of patients treated with SES indicated that new thrombus appeared around uncovered struts despite continuous dual antiplatelet therapy. 19 Long-term follow-up studies using OCT or angioscopy are also required for PES. Although in-stent thrombi and uncovered struts identified by OCT examination at 6-month follow-up may not directly predict the occurrence of LST, prolonged dual antiplatelet therapy for patients treated with DES may be required to prevent LST, regardless of large angiographic late loss.
Study Limitations
The study was non-randomized and included selected and a relatively small number of patients. However, the baseline characteristics of the SES and PES groups were similar. Randomized large-scale studies are required in the future. The present data were not based on serial OCT examination. It was unclear whether in-stent thrombi were residual or newly formed. Finally, neointimal stent coverage by OCT determination probably did not thoroughly reflect pathological endothelialization.
In conclusion, advanced neointimal growth within the first-generation DES as identified by OCT is not associated with a low risk of thrombus. Prolonged dual antiplatelet therapy for patients treated with DES may be required.
